ѻý

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

<ѻý class="mpt-content-deck">— News, features, and commentary about cancer-related issues
MedpageToday
Onco Break over a computer rendering of a cancer cell.

The debate continues over whether some should be called "cancer." (University of California San Francisco)

Delayed treatment related to the correlated with worse survival in stage I non-small cell lung cancer. (Radiology)

Multiple recent market withdrawals of drugs that received have raised concern about the approval process. (BioSpace)

The FDA expanded indications for asciminib (Scemblix) with an accelerated approval for adults with in chronic phase.

And FDA expanded indications for oral liquid methotrexate (Jylamvo) to include , Shorla Oncology announced.

New insights into how burn scars evolve into the aggressive skin cancer . (University of Calgary)

GlycoMimetics announced that a phase II/III trial of the E-selectin antagonist uproleselan plus cytarabine/daunorubicin in newly diagnosed did not meet the primary endpoint of event-free survival.

A shift in the decision-making process, lagging participation in clinical trials, continuing burden of financial toxicity -- a few of the findings from a new . (National Coalition for Cancer Survivorship)

Closer scrutiny of the evidence suggesting the diabetes drug has anticancer activity. (Oncology News Central)

A Texas doctor received a 10-year prison sentence and was ordered to pay $34 million in restitution for his part in a that involved prescribing durable medical equipment and cancer genetics tests for patients he had never met, the Justice Department announced.

A Michigan physician has been charged with a multimillion-dollar scheme involving , the U.S. Attorney's Office for the Eastern District of Michigan announced.

Aided by artificial intelligence, a review of almost 10,000 prostate cancer patients enrolled in clinical trials showed in 42% of cases. (JCO Precision Oncology)

The Biden administration announced another $6 million in grants to support the program in cancer prevention, treatment, and diagnosis.

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined ѻý in 2007.